Ticagrelor, a direct-acting P2Y 12 -receptor antagonist, is rapidly absorbed and partly metabolized to the major metabolite AR-C124910XX (ARC). To identify single-nucleotide polymorphisms (SNPs) associated with pharmacokinetics of ticagrelor and clinical outcomes, we performed a genome-wide association study (GWAS) in patients treated with ticagrelor in the PLATO trial.
Introduction
In the PLATO (PLATelet inhibition and patients Outcome) trial investigating ticagrelor vs. clopidogrel treatment for acute coronary syndromes (ACS), ticagrelor reduced the composite outcome of cardiovascular (CV) death, myocardial infarction (MI), and stroke, but increased non-coronary artery bypass grafting (CABG)-related major bleeding and dyspnoea. 1 Ticagrelor is an oral, reversibly binding adenosine diphosphate receptor antagonist acting via the P2Y 12 -receptor. 2 In contrast to clopidogrel, ticagrelor does not require metabolic activation to exert its antiplatelet effects. 3 Accordingly, compared with clopidogrel, neither the pharmacokinetics (PK) nor the efficacy of ticagrelor are affected by polymorphisms in CYP2C19. 4 The major active metabolite of ticagrelor, AR-C124910XX (ARC), is formed via the most abundant hepatic cytochrome P450 (CYP) enzyme, CYP3A4, and via CYP3A5. 5, 6 AR-C124910XX is present in the blood at about one-third of the concentration of ticagrelor with a similar antiplatelet effect. 5, 7 Ticagrelor is both a substrate and mild inhibitor of CYP3A4, which is why concomitant use with strong CYP3A4 inducers (e.g. rifampin) or inhibitors (e.g. ketoconazole) is contraindicated. For example, co-administration with ketoconazole increased the ticagrelor Cmax and AUCss by 2.4-and 7.3-fold, respectively. 8, 9 Consequently, the use of strong CYP3A4 inhibitors or also potent CYP3A inducers (as they might decrease ticagrelor exposure) was an exclusion criterion in the PLATO trial. 10 The genetic determinants of the PK of ticagrelor and ARC have not previously been reported. We therefore performed a two-stage genome-wide association study (GWAS) of PK within a large subset of the PLATO trial subjects. The aims of this study were to elucidate whether there is a genetic basis for variance in ticagrelor antiplatelet drug exposure and if genetic variability might have impact on clinical efficacy, safety, or tolerability during ticagrelor treatment.
Methods Patients and clinical endpoints
The PLATO trial (NCT00391872) was a randomized clinical phase III trial that compared the effect of ticagrelor vs. clopidogrel on efficacy and safety outcomes for 6 -12 months treatment in 18 624 patients with ACS. A total of 10 013 patients consented for the genetic substudy at time of enrolment. The PK assessment was performed in 6381 patients. For this study, only genotyped patients with available ticagrelor PK data were included in the study population ( Figure 1) . The primary outcome in the PLATO trial was time to the composite endpoint of CV death, MI, and stroke. The study design, performance, outcomes, and detailed endpoint definitions have been published previously. 1, 10 The study was approved by the institutional review boards and performed in accordance with the Declaration of Helsinki. Written informed consent was required before any study procedure.
Genotyping
DNA was extracted from samples of whole blood using Nucleon Genomic DNA Extraction kits (Tepnel Life Sciences, Manchester, UK). A two-stage design was used for the GWAS with a discovery cohort (discovery phase) and a replication cohort (replication phase) ( Figure 1) . The discovery phase consisted of a set of 3998 individuals genotyped using the Illumina HumanOmni2.5-4v1 (Omni2.5) BeadChip (Illumina, San Diego, CA, USA), and replication phase of an additional 6015 individuals, which were genotyped using the Illumina Infinium HumanOmniExpressExome-8v1 BeadChip (Illumina, San Diego, CA, USA). Genotyping was performed according to the manufacturer's instructions on the SNP & SEQ Technology Platform, a part of the Genomics platform of Science for Life Laboratory in Uppsala, Sweden. Analysis of the raw data was performed using Illumina GenomeStudio 2011.1 (Illumina, San Diego, CA, USA), the Illumina's Infinium assay and project sample generated cluster files. 11, 12 Further details on quality control, imputation, and additional genotyping can be found in the Supplementary material online, Methods.
Pharmacokinetic methodology
From the PLATO study, two blood samples were collected from 6381 patients for the determination of plasma concentrations of ticagrelor and ARC; one at post-randomization Visit 1 (on Day 4 post-enrolment or at discharge from the hospital) and the other at Visit 2 (1 month). Plasma concentrations of ticagrelor and ARC were determined using fully validated reversed-phase liquid chromatography/tandem mass spectrometry bioanalytical methods. Lower limits of quantification were 1 and 2.5 ng/mL for ticagrelor and ARC, respectively. 13 A total of 10 818 ticagrelor concentration records and 10 825 ARC concentration records from the 6381 patients were assembled together with the data from the ticagrelor dose administration and individual patient covariate information for the population PK analysis. Individual empirical Bayesian estimates of PK parameters were calculated from the NONMEM program based on the final ticagrelor and ARC PK models. Secondary PK variables, such as AUCss, were then calculated from each patient's empirical Bayesian estimates of relevant PK parameters (AstraZeneca, data on file).
Statistical analysis
Both PK variables were log transformed and analysed using linear regression. We used a feature selection method to select the variables to be included as covariates in the analyses (full list Supplementary material online, Table S2 ). The selection was done on the discovery phase data and involved two steps. Initially, univariate relations of covariates were estimated and then all variables showing univariate association (P , 0.10) were analysed in a multiple model. In the second step, the final set of covariates to adjust for was selected including all variables having P , 0.10 in the multiple regression models for any of the two PK outcomes.
GWAS were performed assuming an additive genetic model, i.e. the genotypes for each single-nucleotide polymorphism (SNP) were coded 0, 1, and 2 and treated as numerical variables. To account for possible population stratification, all analyses were adjusted for the first four genetic principal components.
14 Analyses of non-imputed data were performed using the R-package GenABEL 15 and imputed data were analysed using ProbABEL. 16 The genome-wide significance threshold was set at the Bonferroni limit of P , 3.2 × 10 28 in the discovery phase and SNPs reaching this threshold were taken forward for replication. The significance level for successful replication was set at P ¼ 0.05/number of SNPs for which replication was attempted. In the analyses of the pooled discovery and replication phase data, the genome-wide significance level was set at 1 × 10
28
, which adjusts for 5 million independent tests. Following the genome-wide analyses of the merged and imputed discovery and replication phase data, follow-up analyses were performed by adding each top hit SNP as an additional covariate in a GWAS analysis. This was performed in a sequential manner until no genome-wide significant signals were left.
Statistical analyses of possible single-nucleotide polymorphism effects on clinical outcomes
Selected SNPs associated with PK parameters were evaluated against clinical outcomes using multiple Cox-regression models. The SNPs were analysed assuming an additive model, with adjustment for the same set of covariates as in the GWAS analyses.
To reduce the multiple testing burdens for key outcomes, a primary and secondary set of outcomes and SNPs were selected. The primary set of clinical outcomes was the combined primary outcome (MI, stroke, cardiovascular death), all-cause mortality, all non-CABGrelated bleeding, predominant dyspnoea event, and predominant dyspnoea event within 7 days. The secondary set of clinical outcomes was CV death, MI (excluding silent MI), and major non-CABG-related bleeding. The significance level was estimated using a permutation procedure for the primary and secondary outcome sets separately, where the permutations for the secondary set included all outcomes and SNPs used in both the primary and secondary analyses. This procedure was performed by running all statistical tests, for either the primary set of outcomes or both primary and secondary outcomes, on a permuted data frame. The permutation was conducted keeping dependencies between outcomes intact (i.e. preserving correlations) and between SNPs intact [i.e. preserving linkage disequilibrium (LD)] while removing possible true associations of SNPs with outcomes. For each permutation run, the lowest P-value (based on a likelihood-ratio test) was stored. The procedure was repeated 10 000 times and the lower 5% percentile in the resulting P-value distribution was selected as the P-value cut-off needed to keep the overall type-I error at the 5% limit.
Statistical analyses were performed (unless stated otherwise) using R version 3.0.1 (R foundation for Statistical Computing, Vienna, Austria) Figure 1 Flow chart of patients and data information in different subsets of the PLATO pharmacogenomic substudy.
Effect of genetic variations on ticagrelor plasma levels and DM of clinical data were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results

Background characteristics
The background characteristics of the patients and origin of study samples included in the discovery and replication phase are shown in Table 1 . The background characteristics for genotyped patients were similar to those in the overall PLATO trial with a mean age of 63 years, 69% of patients were male and predominantly Caucasian (99%). We identified 10 variables to include as covariates in the analyses, these were; age, sex, weight, smoking status, concomitant use of CYP3A inducer or moderate/strong inhibitor at baseline, history of hypertension, CABG, or chronic renal disease (glomerular filtration rate ,60 mL/min), and final diagnosis of index event.
Genome-wide association study of ticagrelor active metabolite (AR-C124910XX) and replication
In the discovery analyses (discovery phase), we investigated the PLATO genetics substudy group compromising 1812 patients with PK data ( Figure 1 ). Using genotyped data only, we identified one locus with SNPs surpassing genome-wide significance of P , 3.2 × 10 28 for ARC AUCss on chromosome 12 (Supplementary material online, Figure S1 , Table 2 , and marked with * in Supplementary material online, Table S3 ) with the top hit SNP being rs12371604 (beta ¼ 0.066, P ¼ 9.24 × 10
210
). The identified SNPs are in the solute carrier organic anion transporter family member 1B1 gene (SLCO1B1), which encodes the organic anion transporter polypeptide (OATP) 1B1 transporter. We chose to take two SNPs forward for replication, rs12371604 that was the most significant SNP and rs4149056, which is a known functional variant in SLCO1B1. Effect of genetic variations on ticagrelor plasma levels and rs4149056 passed the P-value threshold for replication [P , 0.05/4 ¼ 0.0125 (where 4 is the total number of SNPs attempted in replication for both PK outcomes)] with P ¼ 1.75 × 10 203 and P ¼ 1.61 × 10 205 , respectively ( Table 2 ).
In the merged and imputed discovery and replication phase analyses of ARC AUCss, two genome-wide significant loci were identified ( Figure 2A and Table 2 ). The top SNP at the SLCO1B1 locus was rs113681054 (P ¼ 3.63 × 10 213 ), which is located downstream of the gene. This SNP is in LD with rs4149056 (r 2 ¼ 0.76). We also found an additional signal on chromosome 4 from a rare SNP (rs61361928, beta ¼ 0.385, P ¼ 3.0 × 10
214
, MAF ¼ 0.5%) in the UDP-glucuronosyltransferase 2B7 gene (UGT2B7). rs113681054 is a functional SNP ( Figure 3B ) that is predicted to be damaging to the protein [Sorting Intolerant From Tolerant (SIFT) score of 0]. Followup analyses adjusting for each top hit SNP in a sequential manner revealed no additional signals. Although imputation quality was high for rs113681054 and rs61361928 (info .0.9), TaqMan genotyping was attempted to verify the results. Due to QC issues, TaqMan genotyping failed for rs113681054 but was successful for rs61361928. The TaqMan genotyped rs61361928 gave a smaller beta estimate, however, still passing the threshold for genome-wide significance (beta ¼ 0.292, P ¼ 2.40 × 10
209
) ( Table 3 ). Genome-wide association study of ticagrelor and replication
In the discovery analyses (discovery phase) of ticagrelor AUCss, we used genotyped SNPs only and identified one SNP surpassing genome-wide significance of P , 3.2 × 10 28 (Supplementary material online, Figure S2 ). This SNP is located on chromosome 7 in the CYP3A4/ CYP3A43 region ( Table 3 ). The two top SNPs, rs117092118 and rs62471929, were taken forward for replication. These SNPs were imputed because they were not present on the chip in the replication phase. One SNP, rs62471929 (P ¼ 6.91 × 10
205
), passed the threshold for replication [P , 0.05/4 ¼ 0.0125 (where 4 is the total number of SNPs attempted in replication for both PK outcomes)], whereas rs117092118 (P ¼ 6.50 × 10 202 ) failed replication. However, the imputation quality for rs117092118 and rs62471929 in the replication phase was poor and decreases the power to detect an association.
In the analyses of imputed and merged discovery and replication phase data, no additional signal was found other than the previous signal coming from the CYP3A4 locus on chromosome 7. The top hit in the merged data came from rs62471956 (P ¼ 1.07 × 10 214 ).
Follow-up analyses adjusting for each top hit SNP in a sequential manner identified an additional independent effect of rs56324128 (beta ¼ 0.424, P ¼ 1.08 × 10
211
) positioned in CYP3A4 ( Figure 4B and Table 3 ). rs56324128 is a functional SNP that is predicted to be damaging to the protein (SIFT score of 0). Due to questionable imputation quality of rs62471956 and rs56324128 (info scores of 0.7), the results were verified and replicated using TaqMan genotyping ( Table 3) .
Association of genetic variants with ticagrelor and ticagrelor active metabolite in the merged data
For further analyses, we choose to use the functional rs4149056 SNP from SLCO1B1 as well as the other three top SNPs from the merged analyses, rs61361928 (UGT2B7), rs62471956 (CYP3A43), and rs56324128 (CYP3A4). For these analyses, genotyped data were used. rs4149056 have been genotyped in both discovery and replication phase as part of the GWAS array, and the other three were genotyped using TaqMan ( Table 2 and Table 3 ). These four selected independent SNPs and their effect on AUCss of ticagrelor and ARC are shown in Figure 5 , Tables 4 and 5. The maximum percent difference for each genotype in geometric mean of AUCss ranged from 6% for the SNPs in SLCO1B1 (ARC) to 54% to that in CYP3A4 (ticagrelor). The SLCO1B1 SNP rs4149056 affected both ARC and ticagrelor concentrations ( Table 5) .
Association of genetic variants with clinical outcomes
In the combined discovery and replication data including 4990 patients, the median follow-up time was 362 days (IQR: 275, 369). The primary outcome (CV death, MI, stroke) occurred in 420 (8.4%) patients, all-cause mortality in 176 (3.5%), CV mortality in 160 (3.2%), MI (excluding silent MI) in 262 (5.3%), non-CABG-related major bleeding in 177 (3.5%), predominant dyspnoea event in 709 (14.2%), dyspnoea within 7 days in 243 (4.9%), and non-CABGrelated major and minor bleeding in 373 (7.5%) patients.
For the purposes of the permutation procedures, the primary SNP was defined as rs4149056 (SLCO1B1) and the secondary SNPs were rs61361928 (UGT2B7), rs62471956 (CYP3A43), and rs56324128 (CYP3A4). The P-value threshold required for declaring significance, determined by permutation, was P , 0.0111 for the primary SNP analysed against the primary set of outcomes [the combined primary endpoint (MI, stroke, and CV death), all-cause mortality, all non-CABG-related bleeding, predominant dyspnoea event, and predominant dyspnoea event within 7 days] and P , 0.0026 for the secondary set permutations [all four SNPs against CV death, MI (excluding silent MI), and major non-CABG-related bleeding, in addition to the primary set of outcomes].
There were no statistically significant associations between any of the top four SNPs identified and the primary or secondary outcomes (Figure 6) . 
Discussion
We report, for the first time, GWAS results on ticagrelor PK in a large cohort of ticagrelor-treated ACS patients and show association of three different genetic loci (SLCO1B1, CYP3A4, and UGT2B7) with ticagrelor levels. Importantly, the modest genetic impact on plasma levels of ticagrelor and the active metabolite (ARC) did not translate into effect on any efficacy or safety endpoints. The PK profile of ticagrelor has been evaluated in different populations, including healthy subjects and patients with ACS, stable coronary artery disease, and atherosclerosis. 17 Ten different metabolites of ticagrelor have been identified. Unchanged ticagrelor and ARC are the major components in plasma. Ticagrelor is mainly metabolized by CYP3A enzymes, of which CYP3A4 and CYP3A5 have been identified as responsible for the formation of ARC. Median time to maximal concentration (tmax) in ACS patients after a loading dose of 180 mg ticagrelor has been reported to be 3 h for ticagrelor and 4 h for ARC. 18 Mean plasma concentrations and peak plasma concentrations (Cmax) of ticagrelor and ARC increase linearly and predictably in a dose-dependent manner. The mean Figure 4 Region plots containing hits in the analysis of the imputed and merged discovery and replication phase data for ticagrelor steady-state area under the curve. Subplot A shows a region (+0.7 Mb) on chromosome 7 surrounding SNP rs62471956 (marked in red) between the CYP3A4 and CYP3A43 genes. Subplot B shows a region (+0.7 Mb) surrounding the top hit after adjusting for rs62471956 (shown in subplot A). The top hit is the functional variant exm638811 (marked in red) from CYP3A4 on chromosome 7. Both subplots A and B are annotated by genes (with exon markings), direction of the gene with a grey arrow, and SIFT score. SIFT score is annotated with 'D' if the score is ≤0.05 and the corresponding SNP P-value is surrounded by a green circle.
elimination half-lives of ticagrelor and ARC are 7.1 -12 and 8.5 -10 h, respectively. 5, 19 Even though CYP3A4 is known to be involved in ticagrelor metabolism, our study is the first to show that a CYP3A4 variant influences the metabolic rate. The CYP3A4 variants that we found to be associated with ticagrelor levels are rare, with minor allele frequencies of 3.4% (rs62471956) and 0.52% (rs56324128). The amino acid substitution resulting from one of these variants is predicted to be damaging to the protein function. However, we did not see any effect of the CYP3A4 variants on the clinical endpoints. This is not surprising since CYP3A4 converts ticagrelor into its active metabolite (ARC), which is equipotent to ticagrelor in its inhibitory effects at the P2Y 12 receptor. We previously genotyped patients in the PLATO trial for CYP2C19 genotypes and the ABCB1 SNP 3435C T and showed no effect from these on either efficacy nor safety in the ticagrelor-treated patients. 4 In contrast to ticagrelor, the efficacy of clopidogrel is hampered by intra-individual variability and genetic polymorphisms contribute to the unpredictable antiplatelet response. 20 The majority of clopidogrel pharmacogenetic research has focused on the CYP enzyme pathway with a strong emphasis on CYP2C19. In clopidogrel-treated patients, CYP2C19 loss-of-functions alleles have been associated with increased risk of ischaemic outcomes. 21 Beyond the CYP P450 enzyme pathway, individuals homozygous for the ABCB1 3435 C . T variant (a gene encoding the efflux transporter P-glycoprotein), have been associated with increased ischaemic adverse events. 22 For prasugrel, a third-generation thienopyridine, the treatment effect is not influenced by either CYP2C19 or ABCB1 polymorphisms.
10 Figure 5 Boxplots of rs4149056/rs61361928 on log(ticagrelor active metabolite steady-state area under the curve) and rs62471956/rs56324128 on log(ticagarelor steady-state area under the curve). Each box consists of the 25, 50 (median), and 75% percentiles. The hinges stretch to the maximum or minimum value within 1.5 times the interquartile range and observations falling outside this range are marked with circles.
Effect of genetic variations on ticagrelor plasma levels
In light of the findings of a pharmacogenetic influence on clopidogrel efficacy, the US Food and Drug Administration (FDA) issued a boxed warning in 2010 against prescribing clopidogrel in patients with CYP2C19 poor metabolizer alleles. However, the clinical utility of testing for CYP2C19 poor metabolizer carrier status is debatable and there is insufficient evidence whether a medical management strategy based on pharmacogenetic testing will result in improved patient-related health outcomes. Nonetheless, a clinical awareness of pharmacogenetics could possibly minimize harmful drug effects, optimize patient care and lead to a better understanding of the genetic determinants of widespread antithrombotic medications.
We identified and replicated SNPs surpassing genome-wide significance that are located within the SLCO1B1 region on chromosome 12. SLCO1B1 encodes a liver-specific member of the organic anion transporter polypeptide (OATP1B1). The protein is a transmembrane receptor that mediates a sodium-independent uptake of numerous endogenous substances and is also involved in the removal of drug compounds. Previous genetic studies have identified SLCO1B1 to regulate the uptake of statins and increase the risk of simvastatin-induced myopathy. 23 The most significant SNP (rs113681054) from our study (in the combined empirical and imputed, combined discovery and replication phase data set) is in LD with another SNP (rs4149056) that is predicted to be damaging These SNPs were associated with the PK variable in the initial GWAS. *P-values can differ slightly from the GWAS results due to differences in underlying statistical software.
to the protein, thus reducing hepatic uptake and leading to increased statin concentrations. 24 Variants in this gene have also been associated with decreased methotrexate clearance and increased gastrointestinal toxicity in children treated for acute lymphoblastic leukaemia. 25 When we examined the effect of the identified SNPs in SLCO1B1 on the geometric mean of the ARC AUCss, the PK effect of each allele was small (6.3%). The variant in SLCO1B1 influences the concentrations of ARC as well as ticagrelor.
We also identified a rare SNP (MAF ¼ 0.5%) in UGT2B7 (rs61361928, P ¼ 3.0 × 10 214 ) associated with ARC AUCss.
UGT2B7 encodes a protein belonging to the UDP-glycosyltransferase (UGT) family responsible for the biotransformation of many drugs and serves a major role in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. For example, the UGT2B7 enzyme catalyses the metabolism of morphine to the main metabolites. Since the deleterious variant in UGT2B7 is associated with higher levels of ARC, but does not affect the ticagrelor levels, we can conclude that the UGT2B7 enzyme is likely involved in the metabolic step downstream of ARC. Although functional polymorphisms have been identified in UGT2B7 predicting interpatient variability in the glucuronidation of drugs, the pathway is confounded with other pathways and it is therefore difficult to estimate the possible extent of drug interactions. When we analysed the identified top SNP hits that were associated with ticagrelor PK (rs4149056 (SLCO1B1), rs61361928 (UGT2B7), rs62471956 (CYP3A43), and rs56324128 (CYP3A4)), we did not find any significant association with any of the primary or secondary outcomes. This might be explained by: (i) the effects of the genetic Figure 6 Forest plot of hazard ratio estimates (with 95% confidence intervals) from the adjusted Cox proportional hazards analyses of the four SNPs rs4149056, rs61361928, rs62471956, and rs56384128 on selected clinical outcomes. None of the SNPs passed the nominal significance level of P , 0.05.
Effect of genetic variations on ticagrelor plasma levels variants on ticagrelor or ARC levels were small or (ii) the enzymes harbouring the genetic variants were associated with the metabolism of ticagrelor into a metabolite with similar pharmacological effects.
Study limitations
A limitation of this study is the absence of a cohort within which to independently verify these findings and to better estimate effect sizes of the reported associations. The known upward bias in effect size observations in initial discoveries (owing to the combination of real effects and random variation favouring increased result ranking) may be a contributory factor in the attenuation of some of the findings in the replication subset, when compared with the discovery subset. Owing to the same effect, it is also possible that the study-wide (combined discovery and replication subset) effect sizes reported here might be subject to downward revision in light of subsequent studies. Moreover, a lack of evidence for genetic associations with clinical outcomes included in this study cannot exclude all possibility of genetic influence, owing to considerations including sampling, statistical power, and coverage of genetic variation. We can, however, exclude large effects of the genetic markers comprising our panel and, to some degree, additional markers indirectly assayed owing to strong LD between variants. A further limitation of the study is that pharmacodynamic (PD) data were not available for a sufficient number of subjects in order to analyse any genetic modulation of PD/ PK relationships. Nevertheless, the unique nature of these data, on SNPs in relation to clinical outcomes during ticagrelor treatment in ACS, has resulted in novel insights into genetic influences on ticagrelor PK and the extent of their impact on clinical outcomes, and the results provide a basis for further study.
Conclusion
In patients with ACS, ticagrelor pharmacokinetics is influenced by three genetic loci (SLCO1B1, UGT2B7, and CYP3A4). However, the modest genetic effects on ticagrelor plasma levels did not translate into any detectable effect on efficacy or safety during ticagrelor treatment. Importantly, we identified two proteins (OATP1B1, UGT2B7) that were previously not known to play a role in ticagrelor metabolism.
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